Navigating menopause care: Expert insights from ACOG 2024
May 19th 2024ACOG
At ACOG 2024, Monica M. Christmas, MD, FACOG, and Stephanie Faubion, MD, emphasize the importance of combating disinformation in menopause care and provide clinicians with evidence-based strategies to manage symptoms effectively.
Empowering ob-gyns to address sexual health concerns
May 18th 2024ACOG
At the 2024 ACOG Annual Clinical & Scientific Meeting, experts emphasized the importance of equipping ob-gyns with the knowledge and tools to address sexual health issues, including hyperactive sexual desire disorder, anorgasmia, and pelvic pain.
New data shows elinzanetant's efficacy in treating menopausal symptoms
May 18th 2024ACOG
Phase 3 data presented by JoAnn Pinkerton, MD, reveals that elinzanetant significantly improves hot flash frequency, sleep, and overall menopause quality of life, offering a promising alternative to estrogen therapy.
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024ACOG
According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Mastering misoprostol: Comprehensive uses across trimesters
May 17th 2024ACOG
Leanne R. McCloskey, MD, and Weronika A. Armstrong, MD, xplore the multifaceted applications of misoprostol in obstetrics, covering protocols, safety, and the impact on birth equity from early pregnancy loss to labor induction at ACOG 2024.
Navigating vasomotor symptoms in breast cancer patients
May 17th 2024ACOG
Michelle Jacobson, MD, MHSc, FRCSC, shares critical perspectives on managing vasomotor symptoms in breast cancer patients at the recent ACOG Annual Clinical & Scientific Meeting, emphasizing the importance of tailored approaches amidst evolving treatment options and patient risks.
Study reveals critical gaps in care for PCOS patients
May 17th 2024ACOG
A new study presented at the 2024 ACOG Annual Clinical and Scientific Meeting highlighted significant gaps in polycystic ovary syndrome (PCOS) care, revealing widespread patient dissatisfaction and the urgent need for improved provider education and comprehensive treatment approaches.
OASIS-1 trial reports reduced VMS frequency and severity from elinzanetant
May 17th 2024ACOG
A recent study showcased at the 2024 ACOG Annual Clinical & Scientific Meeting unveils elinzanetant's efficacy in alleviating vasomotor symptoms, sleep disturbances, and enhancing menopause-related quality of life in postmenopausal women.